Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | F7 | P08709 | 3/20 | 0.46 |
| ▸ | F3 | P13726 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28457926 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL1686087 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL1686066 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL14973588 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL1976522 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL341956 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL1976525 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL1972618 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL1972619 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 | |
| SCHEMBL28583401 | 1.00 | HPGD (0.47) | HPGDTSHRALDH1A1KDM4EF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7090868-B2 | Materials and methods for drug delivery and uptake | UNIVERSITY OF FLORIDA (US) | 2006-08-15 | — | — | US | claimed |
| WO-2004024209-A2 | MATERIALS AND METHODS FOR DRUG DELIVERY AND UPTAKE | UNIVERSITY OF FLORIDA (US) | 2004-03-25 | — | — | WO | claimed |
| US-20040052865-A1 | Materials and methods for drug delivery and uptake | FLORIDA, UNIVERSITY OF | 2004-03-18 | — | — | US | claimed |
| US-8900627-B2 | Compositions for the in vivo delivery of RNAi agents | MIRNA THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2306978-A2 | COMPOSITIONS FOR THE IN VIVO DELIVERY OF RNAI AGENTS | Mirna Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090306194-A1 | NOVEL COMPOSITIONS FOR THE IN VIVO DELIVERY OF RNAI AGENTS | ASURAGEN, INC. | 2009-12-10 | — | — | US | disclosed |
| WO-2009149418-A2 | NOVEL COMPOSITIONS FOR THE IN VIVO DELIVERY OF RNAI AGENTS | ASURAGEN, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20060188562-A1 | Materials and methods for drug delivery and uptake | NATIONAL SCIENCE FOUNDATION | 2006-08-24 | — | — | US | disclosed |
| US-7090868-B2 | Materials and methods for drug delivery and uptake | UNIVERSITY OF FLORIDA (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060165736-A1 | Cosmetic composition | KAO CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060140891-A1 | Cosmetic composition | KAO CORPORATION (JP) | 2006-06-29 | — | — | US | disclosed |
| US-20050137274-A1 | Absorbent articles comprising supercritical fluid treated HIPE, I-HIPE foams and other foams | KO YOUNG C (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004050752-A1 | ABSORBENT ARTICLES COMPRISING SUPERCRITICAL FLUID POLYMERIZED POLYMER______________________________________ | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004044041-A1 | ABSORBENT ARTICLES COMPRISING INVERSE HIPE FOAMS AND OTHER FOAMS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040087926-A1 | Absorbent articles comprising inverse HIPE foams other foams | KIMBERLY-CLARK WORLDWIDE | 2004-05-06 | — | — | US | disclosed |
| WO-2004024209-A2 | MATERIALS AND METHODS FOR DRUG DELIVERY AND UPTAKE | UNIVERSITY OF FLORIDA (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040052865-A1 | Materials and methods for drug delivery and uptake | FLORIDA, UNIVERSITY OF | 2004-03-18 | — | — | US | disclosed |
| US-20030134918-A1 | Absorbent articles comprising supercritical fluid treated HIPE, I-HIPE foams and other foams | KIMBERLY-CLARK WORLDWIDE, INC | 2003-07-17 | — | — | US | disclosed |
| US-6410605-B1 | MIXTURE CONTAINING HYDROPHILIC PARTICLES; WATER IN OIL EMULSION | KAO CORPORATION (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1038573-A2 | Process for preparing emulsion | Kao Corporation (JP) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060165736-A1 | Cosmetic composition | CUTA, DSG1, AQP1 | HPGD 1726/4885TSHR 2913/4885ALDH1A1 2457/4885 |
| US-20060140891-A1 | Cosmetic composition | CUTA, H1-0, H1-5 | HPGD 2297/4885TSHR 2203/4885ALDH1A1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.